Physician profile
Rory Patrick Wildner
NPI 1366960197
$3,392.41
in general payments reported to CMS, 2019-2025
26 companies · $325 in 2025
The $325 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $170 · 2023: $993 · 2024: $1,747 · 2025: $325.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $901.94 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $356.14 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.23 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $243.70 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.19 | 2024 | Farxiga, Breztri, Flumist Quadrivalent |
| Abbott Laboratories | $178.24 | 2021-2024 | Freestyle Libre 3 |
| Inari Medical, INC. | $174.59 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $150.60 | 2024-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $136.45 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $121.60 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $102.70 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $90.32 | 2023-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Janssen Pharmaceuticals, INC | $82.52 | 2023-2024 | Spravato |
| Axsome Therapeutics, INC. | $73.22 | 2023-2025 | Auvelity, Sunosi |
| Dexcom, INC. | $50.09 | 2023-2024 | Dexcom G6 Transmitter |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.58 | 2023 | |
| Alnylam Pharmaceuticals INC. | $27.81 | 2024 | Givlaari |
| Alkermes, INC. | $27.79 | 2023 | Vivitrol |
| Eisai INC. | $23.52 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $22.42 | 2024 | Rexulti |
| Neos Therapeutics, LP | $19.98 | 2024 | Cotempla Xr-Odt |
| Cranial Technologies, INC | $19.90 | 2025 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $18.80 | 2024 | Trintellix |
| Hologic Sales and Service, LLC | $17.69 | 2023 | Aptima, Thinprep 2000 Processor |
| Phadia US INC. | $16.67 | 2025 | Immunocap |
| Collegium Pharmaceutical, INC. | $15.72 | 2023 | Belbuca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rory Wildner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.